SSC
CTXR icon

Syverson Strege & Co’s Citius Pharmaceuticals CTXR Stock Holding History

Syverson Strege & Co’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-86
Closed -$2.51K – 191
2023
Q1 		$2.51K Hold
86
– – ﹤0.01% 442
2022
Q4 		$1.7K Hold
86
– – ﹤0.01% 262
2022
Q3 		$3K Hold
86
– – ﹤0.01% 235
2022
Q2 		$2K Hold
86
– – ﹤0.01% 291
2022
Q1 		$4K Hold
86
– – ﹤0.01% 248
2021
Q4 		$3K Buy
86
+26
+43% +$1.18K ﹤0.01% 257
2021
Q3 		$3K Buy
+60
New +$3.01K ﹤0.01% 370

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Syverson Strege & Co's CTXR Position: Q2 2023 in Review

Syverson Strege & Co sold out of Citius Pharmaceuticals (CTXR) in Q2 2023, closing a stake of 86 shares — an estimated $2.51K sold.

Syverson Strege & Co first reported a position in CTXR in Q3 2021 and held it in 7 quarters. The position peaked at $4K in Q1 2022. 74 funds tracked by Wall St. Rank hold CTXR as of Q2 2023.

  • Syverson Strege & Co reported no remaining Citius Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 86 Citius Pharmaceuticals shares in Q2 2023, an estimated $2.51K.
  • Syverson Strege & Co first reported a position in Citius Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • Syverson Strege & Co's Citius Pharmaceuticals position peaked at $4K in Q1 2022.
  • 74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.